Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Patients in the PHOTON comparator arm received EYLEA® (aflibercept) Injection 2 mg as a fixed 8-week dosing regimen (after five initial monthly doses) for 96 weeks. These patients were then able ...

https://www.tipranks.com/news/the-fly/curis-price-target-lowered-to-20-from-26-at-h-c-wainwright Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

The higher-dose version of the eye disease drug was launched in August 2023 and allows for longer intervals between ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular ...

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) today shared positive results from a three-year extension study of the Phase 3 PHOTON trial, demonstrating that EYLEA HD ...

U.S. Department of Health and Human Services Department of Inspector General: “Review of Medicare Part B Claims for Intravitreal Injections of Eylea and Lucentis.” Medicare: “Macular ...

Eylea's net sales got a boost of about $40 ... was launched in August 2023 and allows for longer intervals between injections for patients. Regeneron's total revenue of $3.72 billion beat ...